| Popis: |
Background: Inflammation plays a central role in COPD and lung cancer carcinogenesis. Inhaled corticosteroids (ICS) reduce inflammation. We investigated whether ICS use are associated with a lower risk of lung cancer. Material and Methods: Data from the Nord-Trondelag Health Study (HUNT2 Survey, 1995-1997) were merged with The Cancer Registry of Norway and Norwegian Cause of Death Registry. Of 65215 participants, those with chronic airway inflammation, defined by FEV1% Results: Among ICS users (N=1095) we found a higher, but not significant, incidence of lung cancer N=39 (3.6%), compared to non-users (N=1946) with N=65 (3.3%) cases. Age and smoking was associated with a higher risk, while sex and lung function was not. After adjusting for confounders, ICS use did not change the risk of lung cancer, hazard ratio (HR) = 0.968, (95% CI, 0.608–1.540) and p-value 0.890. Conclusion: ICS use are not associated with a reduced risk of lung cancer in our population. |
